DP b99

Drug Profile

DP b99

Alternative Names: DP Bapta 99; DP-b99

Latest Information Update: 02 Aug 2015

Price : $50

At a glance

  • Originator D-Pharm
  • Class Antidementias; Ethylenediamines; Neuroprotectants; Small molecules
  • Mechanism of Action Chelating agents; Matrix metalloproteinase 9 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Pancreatitis
  • Preclinical Epilepsy; Malaria; Neurodegenerative disorders; Trypanosomiasis
  • No development reported Brain injuries; CNS trauma
  • Discontinued Alzheimer's disease; Parkinson's disease; Stroke

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 22 Jun 2015 D-Pharm terminates phase II trial in Pancreatitis in Slovakia, Ukraine and Czech Republic (NCT02025049)
  • 12 Jun 2014 Pharmacodynamics data from preclinical studies in Neurodegenerative disorders and Epilepsy released by D-Pharm
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top